FYARRO J Code: J9331

Drug & Product Overview

HCPCS Descriptor Injection, sirolimus protein-bound particles, 1 mg

HCPCS Added Date July 1, 2022

Manufacturer Aadi Bioscience

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Powder, Lyophilized, For Suspension

About FYARRO

Fyarro is a medication aligned to the HCPCS J Code: J9331 for billing, pricing, and reimbursement purposes in the United States. It is an Oncology drug administered via the intravenous route and manufactured by Aadi Bioscience.

According to CMS Drug Use Information: Drug uses not available

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
80803-0153-50	Fyarro	Aadi Bioscience, Inc.	100	100 MG / 20 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

FYARRO Pricing & Reimbursement

J9331 Private Payer Reimbursement

$89.86 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

Sirolimus 505(b)(2) Information:

HCPCS Code	Manufacturer	Active Ingredient	HCPCS Description
J9331	Aadi Bioscience	Sirolimus	Injection, sirolimus protein-bound particles, 1 mg

FYARRO CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

JW / JZ modifiers apply

CMS has identified Fyarro (J9331) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

FYARRO Medically Unlikely Edits (MUE)

The most billing units of J9331 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient

300 units / day

= 300 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

FYARRO Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Malignant perivascular epithelioid cell tumor (PEComa)

Drug Class

Decreased Immunologic Activity [PE]Kinase Inhibitor [EPC]Protein Kinase Inhibitors [MoA]mTOR Inhibitor Immunosuppressant [EPC]mTOR Inhibitors [MoA]

Frequently Asked Questions

Is there an available Fyarro billing and coding guide?

Billing and coding information for FYARRO can be found through Aadi Bioscience. Visit Here →

Are there any available Fyarro patient assistance programs?

FYARRO patient assistance information can be found through Aadi Bioscience. Visit Here →

Where can I find Fyarro prescribing information?

FYARRO prescribing information can be found at the link below: Visit Here →

Where can I find Fyarro side effect information?

Information regarding FYARRO's side effects can be found at MedlinePlus Visit Here →

Does billing FYARRO require JZ/JW wastage modifiers?

CMS has identified FYARRO(J9331) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.